Maybank

Zest

Maybank reaches half of 80 billion ringgit green loans goal

A big chunk of the green loans has been disbursed to support Singapore-based companies' shift to low-carbon source
Maybank Investment Group banks on Asean, set to grow presence and products - THE EDGE SINGAPORE

Zest

Maybank Investment Banking Group banks on Asean, set to grow presence and products

Asean is likely to remain a bright spot amid intensifying headwinds as the region’s resilience is once more on display.

Environmental, Social and Governance

Maybank reaffirms sustainability push with RM4.5 billion earmarked for tech and talent

The bank has mobilised RM38.8 billion of sustainable financing cumulatively from 2021 to end March 2023

Asean

Asean growth 'resilient', faster than China for second consecutive year in 2023: Maybank

Analysts say Asean is emerging as a “defensive harbour” against the backdrop of rising US interest rates and potential recessions.
Recessionary risks still abound in increasingly 'two-sided economy': Analysts - THE EDGE SINGAPORE

Singapore economy

Recessionary risks still abound in increasingly 'two-sided economy': Analysts

Maybank economists have raised the probability of a recession over the next 12 months to 12% as of this month, from 9% in October.
Conviction of two men's conspiracy to hide Russian ownership of accounts upheld - THE EDGE SINGAPORE

In the courts

Conviction of two men's conspiracy to hide Russian ownership of accounts upheld

Tang, who took instructions from Vadim, acted as a nominee director and was declared to be the ultimate beneficial owner

Broker's Calls

DBS and Maybank maintain 'buy' on Aztech, but warn of earnings risks

Analysts have kept their 'buy' calls on Aztech, although they do note the tight supply chain as a risk.
Raffles Medical a 'buy' even though growth set to normalise once pandemic abates - THE EDGE SINGAPORE

Broker's Calls

Raffles Medical a 'buy' even though growth set to normalise once pandemic abates

Ong, Jaiswal, and DBS’ Tan have posted “buy” calls on Raffles Medical at target prices of $1.50, $1.55 and $1.63 respectively.
Analysts mostly satisfied with SGX's 1HFY22 results, for now - THE EDGE SINGAPORE

Broker's Calls

Analysts mostly satisfied with SGX's 1HFY22 results, for now

"There is a risk that securities market turnover, which has already been soft for 1HFY2022, could moderate further."

Broker's Calls

Analysts optimistic on AEM as it expands to take advantage of industry uptrend

With Intel announcing an expansion in Malaysia in Dec 2021, analysts are optimistic on its key test provider, AEM.
×